ID   UBR1_HUMAN              Reviewed;        1749 AA.
AC   Q8IWV7; O60708; O75492; Q14D45; Q68DN9; Q8IWY6; Q96JY4;
DT   16-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   10-MAY-2017, entry version 129.
DE   RecName: Full=E3 ubiquitin-protein ligase UBR1;
DE            EC=2.3.2.27;
DE   AltName: Full=N-recognin-1;
DE   AltName: Full=RING-type E3 ubiquitin transferase UBR1;
DE   AltName: Full=Ubiquitin-protein ligase E3-alpha-1;
DE   AltName: Full=Ubiquitin-protein ligase E3-alpha-I;
GN   Name=UBR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   FUNCTION.
RX   PubMed=15548684; DOI=10.1158/0008-5472.CAN-04-2102;
RA   Kwak K.S., Zhou X., Solomon V., Baracos V.E., Davis J., Bannon A.W.,
RA   Boyle W.J., Lacey D.L., Han H.Q.;
RT   "Regulation of protein catabolism by muscle-specific and cytokine-
RT   inducible ubiquitin ligase E3alpha-II during cancer cachexia.";
RL   Cancer Res. 64:8193-8198(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 18-1727 (ISOFORM 1).
RC   TISSUE=Erythroid cell;
RX   PubMed=12434312; DOI=10.1086/344781;
RA   Dgany O., Avidan N., Delaunay J., Krasnov T., Shalmon L., Shalev H.,
RA   Eidelitz-Markus T., Kapelushnik J., Cattan D., Pariente A.,
RA   Tulliez M., Cretien A., Schischmanoff P.-O., Iolascon A., Fibach E.,
RA   Koren A., Roessler J., Le Merrer M., Yaniv I., Zaizov R.,
RA   Ben-Asher E., Olender T., Lancet D., Beckmann J.S., Tamary H.;
RT   "Congenital dyserythropoietic anemia type I is caused by mutations in
RT   codanin-1.";
RL   Am. J. Hum. Genet. 71:1467-1474(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 166-1014 (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 656-1749 (ISOFORM 2).
RC   TISSUE=Heart;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 702-1034 (ISOFORM 1), AND
RP   TISSUE SPECIFICITY.
RX   PubMed=9653112; DOI=10.1073/pnas.95.14.7898;
RA   Kwon Y.T., Reiss Y., Fried V.A., Hershko A., Yoon J.K., Gonda D.K.,
RA   Sangan P., Copeland N.G., Jenkins N.A., Varshavsky A.;
RT   "The mouse and human genes encoding the recognition component of the
RT   N-end rule pathway.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:7898-7903(1998).
RN   [7]
RP   INTERACTION WITH RECQL4, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15317757; DOI=10.1093/hmg/ddh269;
RA   Yin J., Kwon Y.T., Varshavsky A., Wang W.;
RT   "RECQL4, mutated in the Rothmund-Thomson and RAPADILINO syndromes,
RT   interacts with ubiquitin ligases UBR1 and UBR2 of the N-end rule
RT   pathway.";
RL   Hum. Mol. Genet. 13:2421-2430(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1179, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-21, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT THR-21, CLEAVAGE OF INITIATOR METHIONINE [LARGE
RP   SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-21, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   FUNCTION.
RX   PubMed=20298436; DOI=10.1111/j.1365-2443.2010.01385.x;
RA   Kume K., Iizumi Y., Shimada M., Ito Y., Kishi T., Yamaguchi Y.,
RA   Handa H.;
RT   "Role of N-end rule ubiquitin ligases UBR1 and UBR2 in regulating the
RT   leucine-mTOR signaling pathway.";
RL   Genes Cells 15:339-349(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-21, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-21, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 98-167 ALONE AND IN COMPLEX
RP   WITH N-END RULE PEPTIDE, UBR-TYPE ZINC-FINGER, FUNCTION, AND VARIANT
RP   JB5 ARG-136.
RX   PubMed=20835242; DOI=10.1038/nsmb.1894;
RA   Matta-Camacho E., Kozlov G., Li F.F., Gehring K.;
RT   "Structural basis of substrate recognition and specificity in the N-
RT   end rule pathway.";
RL   Nat. Struct. Mol. Biol. 17:1182-1187(2010).
RN   [16]
RP   VARIANTS JBS ARG-136 AND SER-1279, FUNCTION, DISEASE, TISSUE
RP   SPECIFICITY, SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=16311597; DOI=10.1038/ng1681;
RA   Zenker M., Mayerle J., Lerch M.M., Tagariello A., Zerres K.,
RA   Durie P.R., Beier M., Hulskamp G., Guzman C., Rehder H., Beemer F.A.,
RA   Hamel B.C.J., Vanlieferinghen P., Gershoni-Baruch R., Vieira M.W.,
RA   Dumic M., Auslender R., Gil-da-Silva-Lopes V.L., Steinlicht S.,
RA   Rauh M., Shalev S.A., Thiel C., Winterpacht A., Kwon Y.T.,
RA   Varshavsky A., Reis A.;
RT   "Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway,
RT   causes pancreatic dysfunction, malformations and mental retardation
RT   (Johanson-Blizzard syndrome).";
RL   Nat. Genet. 37:1345-1350(2005).
RN   [17]
RP   VARIANTS JBS LEU-122; ARG-136 AND GLU-1102, AND CHARACTERIZATION OF
RP   VARIANTS JBS LEU-122; ARG-136 AND GLU-1102.
RX   PubMed=21931868; DOI=10.1371/journal.pone.0024925;
RA   Hwang C.S., Sukalo M., Batygin O., Addor M.C., Brunner H., Aytes A.P.,
RA   Mayerle J., Song H.K., Varshavsky A., Zenker M.;
RT   "Ubiquitin ligases of the N-end rule pathway: assessment of mutations
RT   in UBR1 that cause the Johanson-Blizzard syndrome.";
RL   PLoS ONE 6:E24925-E24925(2011).
RN   [18]
RP   VARIANT JBS PRO-700.
RX   PubMed=22072859; DOI=10.3748/wjg.v17.i37.4247;
RA   Almashraki N., Abdulnabee M.Z., Sukalo M., Alrajoudi A.,
RA   Sharafadeen I., Zenker M.;
RT   "Johanson-Blizzard syndrome.";
RL   World J. Gastroenterol. 17:4247-4250(2011).
RN   [19]
RP   VARIANTS JBS LEU-122; PHE-127; ARG-136; ARG-166; ARG-217; ARG-286;
RP   PRO-317; 389-ALA--PHE-392 DEL; ASP-563; VAL-660 DEL; PRO-700; CYS-754;
RP   HIS-754; GLU-1102; GLY-1242; SER-1279; LEU-1426; PHE-1427; PRO-1431
RP   AND ARG-1661.
RX   PubMed=24599544; DOI=10.1002/humu.22538;
RA   Sukalo M., Fiedler A., Guzman C., Spranger S., Addor M.C.,
RA   McHeik J.N., Oltra Benavent M., Cobben J.M., Gillis L.A., Shealy A.G.,
RA   Deshpande C., Bozorgmehr B., Everman D.B., Stattin E.L., Liebelt J.,
RA   Keller K.M., Bertola D.R., van Karnebeek C.D., Bergmann C., Liu Z.,
RA   Dueker G., Rezaei N., Alkuraya F.S., Ogur G., Alrajoudi A.,
RA   Venegas-Vega C.A., Verbeek N.E., Richmond E.J., Kirbiyik O.,
RA   Ranganath P., Singh A., Godbole K., Ali F.A., Alves C., Mayerle J.,
RA   Lerch M.M., Witt H., Zenker M.;
RT   "Mutations in the human UBR1 gene and the associated phenotypic
RT   spectrum.";
RL   Hum. Mutat. 35:521-531(2014).
RN   [20]
RP   VARIANT JBS ARG-427.
RX   PubMed=26149651; DOI=10.1016/j.gene.2015.06.082;
RA   Atik T., Karakoyun M., Sukalo M., Zenker M., Ozkinay F., Aydogdu S.;
RT   "Two novel UBR1 gene mutations in a patient with Johanson Blizzard
RT   Syndrome: A mild phenotype without mental retardation.";
RL   Gene 570:153-155(2015).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which is a component of the
CC       N-end rule pathway. Recognizes and binds to proteins bearing
CC       specific N-terminal residues that are destabilizing according to
CC       the N-end rule, leading to their ubiquitination and subsequent
CC       degradation. May be involved in pancreatic homeostasis. Binds
CC       leucine and is a negative regulator of the leucine-mTOR signaling
CC       pathway, thereby controlling cell growth.
CC       {ECO:0000269|PubMed:15548684, ECO:0000269|PubMed:16311597,
CC       ECO:0000269|PubMed:20298436, ECO:0000269|PubMed:20835242}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with RECQL4. {ECO:0000269|PubMed:15317757,
CC       ECO:0000269|PubMed:20835242}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:16311597}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8IWV7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IWV7-2; Sequence=VSP_015164, VSP_015165;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Broadly expressed, with highest levels in
CC       skeletal muscle, kidney and pancreas. Present in acinar cells of
CC       the pancreas (at protein level). {ECO:0000269|PubMed:15548684,
CC       ECO:0000269|PubMed:16311597, ECO:0000269|PubMed:9653112}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal pancreas.
CC       {ECO:0000269|PubMed:16311597}.
CC   -!- DOMAIN: The RING-H2 zinc finger is an atypical RING finger with a
CC       His ligand in place of the fourth Cys of the classical motif.
CC   -!- DOMAIN: The UBR-type zinc finger forms a pocket that mediates
CC       recognition of type 1 N-degrons. It exhibits preference for
CC       Arginine in first position, has poor affinity for histidine, and
CC       doesn't bind acetylated peptides.
CC   -!- DISEASE: Johanson-Blizzard syndrome (JBS) [MIM:243800]: This
CC       disorder includes congenital exocrine pancreatic insufficiency,
CC       multiple malformations such as nasal wing aplasia, and frequent
CC       mental retardation. Pancreas of individuals with JBS do not
CC       express UBR1 and show intrauterine-onset destructive pancreatitis.
CC       {ECO:0000269|PubMed:16311597, ECO:0000269|PubMed:21931868,
CC       ECO:0000269|PubMed:22072859, ECO:0000269|PubMed:24599544,
CC       ECO:0000269|PubMed:26149651}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the UBR1 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB55380.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY061886; AAL32103.1; -; mRNA.
DR   EMBL; BC113505; AAI13506.1; -; mRNA.
DR   EMBL; BC113507; AAI13508.1; -; mRNA.
DR   EMBL; AF525401; AAO14997.1; -; mRNA.
DR   EMBL; AK027803; BAB55380.1; ALT_INIT; mRNA.
DR   EMBL; CR749326; CAH18181.1; -; mRNA.
DR   EMBL; AF061556; AAC39845.1; -; mRNA.
DR   EMBL; AH006181; AAC23677.1; -; Genomic_DNA.
DR   CCDS; CCDS10091.1; -. [Q8IWV7-1]
DR   RefSeq; NP_777576.1; NM_174916.2. [Q8IWV7-1]
DR   UniGene; Hs.591121; -.
DR   PDB; 3NY1; X-ray; 2.08 A; A/B=97-168.
DR   PDB; 5TDC; X-ray; 1.61 A; A/C=98-168.
DR   PDBsum; 3NY1; -.
DR   PDBsum; 5TDC; -.
DR   ProteinModelPortal; Q8IWV7; -.
DR   SMR; Q8IWV7; -.
DR   BioGrid; 128238; 84.
DR   DIP; DIP-47033N; -.
DR   IntAct; Q8IWV7; 32.
DR   MINT; MINT-1417571; -.
DR   STRING; 9606.ENSP00000290650; -.
DR   iPTMnet; Q8IWV7; -.
DR   PhosphoSitePlus; Q8IWV7; -.
DR   BioMuta; UBR1; -.
DR   DMDM; 73622071; -.
DR   EPD; Q8IWV7; -.
DR   MaxQB; Q8IWV7; -.
DR   PaxDb; Q8IWV7; -.
DR   PeptideAtlas; Q8IWV7; -.
DR   PRIDE; Q8IWV7; -.
DR   Ensembl; ENST00000290650; ENSP00000290650; ENSG00000159459. [Q8IWV7-1]
DR   GeneID; 197131; -.
DR   KEGG; hsa:197131; -.
DR   UCSC; uc001zqq.4; human. [Q8IWV7-1]
DR   CTD; 197131; -.
DR   DisGeNET; 197131; -.
DR   GeneCards; UBR1; -.
DR   HGNC; HGNC:16808; UBR1.
DR   HPA; HPA038838; -.
DR   MalaCards; UBR1; -.
DR   MIM; 243800; phenotype.
DR   MIM; 605981; gene.
DR   neXtProt; NX_Q8IWV7; -.
DR   OpenTargets; ENSG00000159459; -.
DR   Orphanet; 2315; Johanson-Blizzard syndrome.
DR   PharmGKB; PA38187; -.
DR   eggNOG; KOG1140; Eukaryota.
DR   eggNOG; ENOG410XPQU; LUCA.
DR   GeneTree; ENSGT00530000063055; -.
DR   HOVERGEN; HBG080426; -.
DR   InParanoid; Q8IWV7; -.
DR   KO; K10625; -.
DR   OMA; NTEPLAQ; -.
DR   OrthoDB; EOG091G009K; -.
DR   PhylomeDB; Q8IWV7; -.
DR   TreeFam; TF323875; -.
DR   BRENDA; 3.4.17.20; 2681.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SIGNOR; Q8IWV7; -.
DR   UniPathway; UPA00143; -.
DR   EvolutionaryTrace; Q8IWV7; -.
DR   GeneWiki; UBR1; -.
DR   GenomeRNAi; 197131; -.
DR   PRO; PR:Q8IWV7; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000159459; -.
DR   CleanEx; HS_UBR1; -.
DR   ExpressionAtlas; Q8IWV7; baseline and differential.
DR   Genevisible; Q8IWV7; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0000502; C:proteasome complex; IEA:Ensembl.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IBA:GO_Central.
DR   GO; GO:0070728; F:leucine binding; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0071233; P:cellular response to leucine; IDA:UniProtKB.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; IMP:UniProtKB.
DR   GO; GO:0071596; P:ubiquitin-dependent protein catabolic process via the N-end rule pathway; IBA:GO_Central.
DR   Gene3D; 3.30.1390.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR003769; ClpS_core.
DR   InterPro; IPR014719; Ribosomal_L7/12_C/ClpS-like.
DR   InterPro; IPR011991; WHTH_DNA-bd_dom.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR003126; Znf_UBR.
DR   Pfam; PF02617; ClpS; 1.
DR   Pfam; PF02207; zf-UBR; 1.
DR   SMART; SM00396; ZnF_UBR1; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   SUPFAM; SSF54736; SSF54736; 1.
DR   PROSITE; PS51157; ZF_UBR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Disease mutation; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transferase;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19369195}.
FT   CHAIN         2   1749       E3 ubiquitin-protein ligase UBR1.
FT                                /FTId=PRO_0000056136.
FT   ZN_FING      97    168       UBR-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00508}.
FT   ZN_FING    1098   1201       RING-type; atypical.
FT   COMPBIAS    864    869       Poly-Pro.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES      21     21       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1179   1179       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332}.
FT   VAR_SEQ     795    803       NNETGLENV -> TRCIRPWSL (in isoform 2).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_015164.
FT   VAR_SEQ     804   1749       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_015165.
FT   VARIANT     122    122       V -> L (in JBS; decreased, but detectable
FT                                activity in a yeast-based assay).
FT                                {ECO:0000269|PubMed:21931868,
FT                                ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075179.
FT   VARIANT     127    127       C -> F (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075180.
FT   VARIANT     136    136       H -> R (in JBS; prevents proper folding
FT                                of the UBR-type zinc finger; may decrease
FT                                protein stability; loss of activity in a
FT                                yeast-based assay; dbSNP:rs119477054).
FT                                {ECO:0000269|PubMed:16311597,
FT                                ECO:0000269|PubMed:20835242,
FT                                ECO:0000269|PubMed:21931868,
FT                                ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_024741.
FT   VARIANT     166    166       H -> R (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075181.
FT   VARIANT     217    217       L -> R (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075182.
FT   VARIANT     286    286       I -> R (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075183.
FT   VARIANT     317    317       L -> P (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075184.
FT   VARIANT     389    392       Missing (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075185.
FT   VARIANT     427    427       L -> R (in JBS; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26149651}.
FT                                /FTId=VAR_075186.
FT   VARIANT     563    563       A -> D (in JBS; dbSNP:rs768686147).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075187.
FT   VARIANT     596    596       K -> M (in dbSNP:rs34568456).
FT                                /FTId=VAR_034467.
FT   VARIANT     660    660       Missing (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075188.
FT   VARIANT     700    700       S -> P (in JBS).
FT                                {ECO:0000269|PubMed:22072859,
FT                                ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075189.
FT   VARIANT     754    754       R -> C (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075190.
FT   VARIANT     754    754       R -> H (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075191.
FT   VARIANT     899    899       I -> V (in dbSNP:rs35069201).
FT                                /FTId=VAR_052116.
FT   VARIANT    1102   1102       Q -> E (in JBS; strong decrease in
FT                                activity in a yeast-based assay).
FT                                {ECO:0000269|PubMed:21931868,
FT                                ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075192.
FT   VARIANT    1242   1242       R -> G (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075193.
FT   VARIANT    1279   1279       G -> S (in JBS).
FT                                {ECO:0000269|PubMed:16311597,
FT                                ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_024742.
FT   VARIANT    1426   1426       P -> L (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075194.
FT   VARIANT    1427   1427       S -> F (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075195.
FT   VARIANT    1431   1431       S -> P (in JBS; dbSNP:rs140972409).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075196.
FT   VARIANT    1548   1548       T -> A (in dbSNP:rs3917223).
FT                                /FTId=VAR_061822.
FT   VARIANT    1661   1661       G -> R (in JBS).
FT                                {ECO:0000269|PubMed:24599544}.
FT                                /FTId=VAR_075197.
FT   CONFLICT    201    201       V -> A (in Ref. 4). {ECO:0000305}.
FT   CONFLICT    900    900       D -> N (in Ref. 6; AAC39845).
FT                                {ECO:0000305}.
FT   CONFLICT    973    973       D -> T (in Ref. 3; AAO14997).
FT                                {ECO:0000305}.
FT   CONFLICT    993    993       C -> S (in Ref. 6; AAC23677).
FT                                {ECO:0000305}.
FT   CONFLICT   1710   1719       LSRERYRKLH -> FLVSGTEAP (in Ref. 3).
FT                                {ECO:0000305}.
FT   CONFLICT   1722   1722       W -> R (in Ref. 3). {ECO:0000305}.
FT   STRAND      108    112       {ECO:0000244|PDB:3NY1}.
FT   TURN        113    115       {ECO:0000244|PDB:3NY1}.
FT   STRAND      116    118       {ECO:0000244|PDB:3NY1}.
FT   HELIX       125    128       {ECO:0000244|PDB:3NY1}.
FT   HELIX       132    135       {ECO:0000244|PDB:3NY1}.
FT   STRAND      138    142       {ECO:0000244|PDB:3NY1}.
FT   STRAND      156    159       {ECO:0000244|PDB:3NY1}.
FT   TURN        164    166       {ECO:0000244|PDB:3NY1}.
SQ   SEQUENCE   1749 AA;  200211 MW;  3AE0E1A749884971 CRC64;
     MADEEAGGTE RMEISAELPQ TPQRLASWWD QQVDFYTAFL HHLAQLVPEI YFAEMDPDLE
     KQEESVQMSI FTPLEWYLFG EDPDICLEKL KHSGAFQLCG RVFKSGETTY SCRDCAIDPT
     CVLCMDCFQD SVHKNHRYKM HTSTGGGFCD CGDTEAWKTG PFCVNHEPGR AGTIKENSRC
     PLNEEVIVQA RKIFPSVIKY VVEMTIWEEE KELPPELQIR EKNERYYCVL FNDEHHSYDH
     VIYSLQRALD CELAEAQLHT TAIDKEGRRA VKAGAYAACQ EAKEDIKSHS ENVSQHPLHV
     EVLHSEIMAH QKFALRLGSW MNKIMSYSSD FRQIFCQACL REEPDSENPC LISRLMLWDA
     KLYKGARKIL HELIFSSFFM EMEYKKLFAM EFVKYYKQLQ KEYISDDHDR SISITALSVQ
     MFTVPTLARH LIEEQNVISV ITETLLEVLP EYLDRNNKFN FQGYSQDKLG RVYAVICDLK
     YILISKPTIW TERLRMQFLE GFRSFLKILT CMQGMEEIRR QVGQHIEVDP DWEAAIAIQM
     QLKNILLMFQ EWCACDEELL LVAYKECHKA VMRCSTSFIS SSKTVVQSCG HSLETKSYRV
     SEDLVSIHLP LSRTLAGLHV RLSRLGAVSR LHEFVSFEDF QVEVLVEYPL RCLVLVAQVV
     AEMWRRNGLS LISQVFYYQD VKCREEMYDK DIIMLQIGAS LMDPNKFLLL VLQRYELAEA
     FNKTISTKDQ DLIKQYNTLI EEMLQVLIYI VGERYVPGVG NVTKEEVTMR EIIHLLCIEP
     MPHSAIAKNL PENENNETGL ENVINKVATF KKPGVSGHGV YELKDESLKD FNMYFYHYSK
     TQHSKAEHMQ KKRRKQENKD EALPPPPPPE FCPAFSKVIN LLNCDIMMYI LRTVFERAID
     TDSNLWTEGM LQMAFHILAL GLLEEKQQLQ KAPEEEVTFD FYHKASRLGS SAMNIQMLLE
     KLKGIPQLEG QKDMITWILQ MFDTVKRLRE KSCLIVATTS GSESIKNDEI THDKEKAERK
     RKAEAARLHR QKIMAQMSAL QKNFIETHKL MYDNTSEMPG KEDSIMEEES TPAVSDYSRI
     ALGPKRGPSV TEKEVLTCIL CQEEQEVKIE NNAMVLSACV QKSTALTQHR GKPIELSGEA
     LDPLFMDPDL AYGTYTGSCG HVMHAVCWQK YFEAVQLSSQ QRIHVDLFDL ESGEYLCPLC
     KSLCNTVIPI IPLQPQKINS ENADALAQLL TLARWIQTVL ARISGYNIRH AKGENPIPIF
     FNQGMGDSTL EFHSILSFGV ESSIKYSNSI KEMVILFATT IYRIGLKVPP DERDPRVPML
     TWSTCAFTIQ AIENLLGDEG KPLFGALQNR QHNGLKALMQ FAVAQRITCP QVLIQKHLVR
     LLSVVLPNIK SEDTPCLLSI DLFHVLVGAV LAFPSLYWDD PVDLQPSSVS SSYNHLYLFH
     LITMAHMLQI LLTVDTGLPL AQVQEDSEEA HSASSFFAEI SQYTSGSIGC DIPGWYLWVS
     LKNGITPYLR CAALFFHYLL GVTPPEELHT NSAEGEYSAL CSYLSLPTNL FLLFQEYWDT
     VRPLLQRWCA DPALLNCLKQ KNTVVRYPRK RNSLIELPDD YSCLLNQASH FRCPRSADDE
     RKHPVLCLFC GAILCSQNIC CQEIVNGEEV GACIFHALHC GAGVCIFLKI RECRVVLVEG
     KARGCAYPAP YLDEYGETDP GLKRGNPLHL SRERYRKLHL VWQQHCIIEE IARSQETNQM
     LFGFNWQLL
//
